Retatrutide Results Timeline: What the Phase 2 Trials Actually Show

Retatrutide (development code LY3437943) is an investigational injectable peptide that activates three metabolic receptors at once: the GIP receptor, the GLP-1 receptor, and the glucagon receptor. It is sometimes called a triple agonist or tri-agonist. This distinguishes it from semaglutide, which acts only on GLP-1, and from tirzepatide, which acts on GIP and GLP-1 but not glucagon. Adding controlled glucagon receptor activity is thought to increase energy expenditure and influence liver fat, on top of the appetite and glucose effects shared with the GLP-1 class.

Understanding the results timeline matters because weight loss with these agents is not instantaneous and not linear. The dose is deliberately started low and increased in steps over several weeks to improve tolerability, so early weeks reflect a sub-therapeutic dose. Readers who expect a fixed monthly figure often misread their own progress. A realistic month-by-month picture, drawn from published trial data rather than anecdote, gives a more honest baseline for what the molecule does over time.

The most informative human data come from a Phase 2 obesity trial published in the New England Journal of Medicine in 2023 and a parallel Phase 2 trial in type 2 diabetes published in The Lancet. Both used dose escalation and followed participants for roughly 36 to 48 weeks. Everything in this article is drawn from those studies and should be read as trial averages, not individual guarantees.

Retatrutide belongs to the broader family of incretin-based peptides. If you are new to how these molecules work at the receptor level, our overview of the GLP-1 pathway and our primer on what peptides are provide useful background. This article is educational only and does not describe a dosing protocol.

In the Phase 2 obesity trial (338 adults with obesity, 48 weeks), the weight-loss curve followed a recognizable shape. The first phase, roughly weeks 0 to 4, produced modest but measurable loss while participants were still on the lowest starting dose. This is the tolerability window, and the numbers here are small on purpose.

The second phase, roughly weeks 4 to 24, is where most of the visible change happened. As the dose climbed toward the target, the rate of weekly weight loss accelerated. By around 24 weeks, participants on the higher doses had already lost a large fraction of their eventual total. This middle window is typically when people notice the clearest changes in appetite, portion size, and clothing fit.

The third phase, roughly weeks 24 to 48, showed continued but gradually slowing loss at the group level. Importantly, the curve did not flatten into a clear plateau by week 48, which is unusual for a study of that length and is discussed in its own section below.

A simplified view of the highest-dose (12 mg) group looks like this:

These figures are read from published trial graphs and least-squares means and are rounded. Individual results in a trial vary widely around these averages, and this is not a prediction for any specific person.

Retatrutide showed a clear dose-response relationship: higher target doses produced larger average weight loss. The Phase 2 obesity trial tested target doses of 1 mg, 4 mg, 8 mg, and 12 mg against placebo, with weekly subcutaneous injection.

At 48 weeks, the least-squares mean changes in body weight were approximately -8.7% for 1 mg, -17.1% for 4 mg, -22.8% for 8 mg, and -24.2% for 12 mg, versus about -2.1% for placebo. In practical terms, the two highest doses moved roughly a fifth to a quarter of total body weight over about eleven months.

The monthly pace differs by dose because escalation schedules differ. Lower-dose arms reach their target sooner and level off earlier, while the 8 mg and 12 mg arms keep climbing longer. A rough by-dose picture at three checkpoints:

Two patterns stand out. First, roughly half to two-thirds of the eventual weight loss at the top dose had already occurred by the 24-week mark, so the first six months carry most of the visible momentum. Second, the gap between doses widens over time, meaning the benefit of a higher dose is expressed mostly in the second half of the year rather than the first few weeks. Because retatrutide is investigational, these dose figures describe trial conditions under medical supervision and are not a recommendation to self-administer.

The single most common question is how retatrutide stacks up against the two approved incretin agents. The honest answer is that no head-to-head randomized trial has been published, so any comparison is cross-trial and imperfect. Different studies enroll different populations, run for different durations, and use different escalation schedules. With that caveat, the published averages allow a broad comparison.

In the STEP program, semaglutide (2.4 mg weekly) produced average weight loss around 15% to 17% of body weight over 68 weeks. In the SURMOUNT program, tirzepatide reached roughly 20% to 22% over 72 weeks at the highest dose. Retatrutide's approximately 24.2% at 48 weeks is therefore a larger figure over a shorter window, though the trial was smaller and Phase 2 rather than Phase 3.

On pace rather than final magnitude, retatrutide's curve appears at least as steep as tirzepatide's and clearly steeper than semaglutide's during comparable early months, which many observers attribute to the added glucagon receptor activity increasing energy expenditure. Still, Phase 2 results in a selected population often look more favorable than later Phase 3 results in broader populations, so these numbers may narrow once large trials report. Treat the comparison as directional, not definitive.

Weight is only part of the picture. A separate Phase 2 trial in adults with type 2 diabetes (published in The Lancet, 36 weeks) measured glycemic and metabolic outcomes alongside weight. Here the timeline for blood sugar improvement is faster than for weight, because incretin agents lower glucose quickly once therapeutic exposure is reached.

Reductions in HbA1c (a marker of average blood glucose over about three months) were seen within the first 12 weeks and largely stabilized by around 24 to 36 weeks. At the higher doses, average HbA1c reductions were substantial and brought many participants toward or into the non-diabetic range during the trial, though this was under close supervision.

Weight loss in the diabetes trial was somewhat smaller than in the obesity trial at comparable doses, reaching roughly 16% to 17% at the top dose over 36 weeks. This diabetes-versus-obesity gap in weight response is consistent with what has been observed for other incretin agents and is a normal feature of these populations.

The glucagon receptor component deserves a note. Glucagon can, in isolation, raise blood glucose, so a triple agonist has to balance that against the strong glucose-lowering effect of GLP-1. In the trials, the net effect on glucose was clearly favorable, and no signal of worsened glycemic control emerged. Investigators also reported early signals on liver fat, a marker relevant to metabolic-associated fatty liver disease, which is being studied further. This section describes trial findings and is not medical advice; anyone managing diabetes should work only with their own clinician and review our medical disclaimer.

Side effects with retatrutide followed a predictable timeline tied to dose escalation. The overwhelming majority were gastrointestinal, dose-dependent, and most frequent during the weeks when the dose was being raised. This is the same tolerability pattern seen across the incretin class.

During the early phase (weeks 0 to 12), the most common events were nausea, diarrhea, vomiting, and constipation. In the trials these were mostly mild to moderate and tended to appear or worsen shortly after each dose step, then settle. This is precisely why the escalation is gradual rather than starting at the target dose.

During the middle and later phases (weeks 12 to 48), gastrointestinal complaints generally became less frequent as participants adapted to a stable dose. A dose-dependent increase in heart rate was observed, consistent with other incretin agents and generally modest, and is monitored in ongoing studies. Some participants reported cutaneous sensory changes such as skin hyperesthesia, which drew attention but was typically transient.

Discontinuation due to adverse events rose with dose but remained a minority of participants. No unexpected severe safety signal was reported in Phase 2, though a Phase 2 trial is too small to detect rare events, which is one reason Phase 3 exists. A simplified phase view:

Because retatrutide is not approved, its full safety profile is not established. This is educational information, not a safety guarantee, and no incretin agent is free of side effects.

One of the most discussed findings from the Phase 2 obesity trial is that, at the higher doses, the weight-loss curve had not clearly flattened by the end of the 48-week study. In most weight-loss trials, the curve bends toward a plateau well before that point as the body reaches a new energy balance. Retatrutide's 8 mg and 12 mg groups were still trending downward.

There are a few plausible explanations, none confirmed. The glucagon receptor component may sustain elevated energy expenditure in a way that pure GLP-1 or GLP-1/GIP agents do not, delaying the metabolic adaptation that usually stalls weight loss. Alternatively, the 48-week window may simply have been too short to reach the true nadir at the highest doses.

The practical implication is important but must be stated carefully. A curve that is still descending at 48 weeks does not prove that loss continues indefinitely; it only means the endpoint of the trial was reached before a plateau. The eventual maximum could be higher than 24.2%, or the curve could flatten shortly after the study ended. Only longer trials can distinguish these.

This is exactly the kind of open question that Phase 3 is designed to resolve, with larger samples and longer follow-up. Until then, the responsible reading is that retatrutide's ceiling is not yet known, and early Phase 2 optimism should be tempered by the history of effect sizes shrinking somewhat in larger studies. For readers tracking their own metrics over time, a structured log such as a peptide tracker can help separate genuine trends from week-to-week noise.

As of 2026, retatrutide is investigational. It is not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other major regulators for any indication. It can be used lawfully in humans only within the context of a regulated clinical trial.

Development has moved into Phase 3, the large-scale stage that determines whether a drug reaches the market. The Phase 3 program spans obesity, type 2 diabetes, and related metabolic conditions, and includes a cardiovascular and clinical-outcomes component. These trials enroll thousands of participants and run for one to several years, which is why approval, if it comes, would take time.

Because it is unapproved, retatrutide sold outside a clinical trial is generally labeled as a research chemical and is marketed for laboratory research use only. Product purity, identity, and dosing accuracy from such sources are not verified by any regulator, and using an investigational peptide outside medical supervision carries real and poorly quantified risk. Legal status varies by jurisdiction.

We do not provide dosing protocols for unapproved peptides, and nothing here should be read as encouragement to obtain or self-administer retatrutide. If you are exploring approved options for weight or metabolic health, those conversations belong with a licensed clinician. You can review general safety context in our medical disclaimer, and browse educational material rather than purchase pages for background. Approved GLP-1 and GLP-1/GIP agents already exist and are the appropriate starting point for any legitimate clinical discussion.

Pulling the timeline together, the trial data support a few realistic expectations, always with the caveat that these are group averages under medical supervision and that retatrutide remains investigational.

First, early weeks are quiet by design. Because the dose starts low, the first month produces only modest loss. Judging the molecule by week 4 understates its later effect. Second, months 2 through 6 carry the momentum, and this is where trial participants saw the clearest change. Third, the second half of the year separates the doses, with higher doses continuing to diverge from lower ones.

Equally important is what the data do not promise. Individual variation in a trial is large, so some participants lose far less than the average and a few lose more. Weight loss depends on continued treatment; when incretin agents are stopped, partial regain is common, a pattern well documented for the approved members of the class. And a Phase 2 result is a preliminary signal, not a final verdict.

For context on how retatrutide fits among related molecules, our overview of the GLP-1 receptor family explains the mechanistic differences between single, dual, and triple agonists. For foundational concepts, see our guide to peptides and how they work.

Medical disclaimer: This article is for educational purposes only and is not medical advice. Retatrutide is not approved for human use and is not a treatment you should obtain or self-administer. Consult a qualified healthcare professional before making any decision about weight management or metabolic health, and never use an investigational or research-only peptide outside a supervised clinical setting.